Adlai Nortye Ltd.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Adlai Nortye Ltd..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.88 $ to 16.60 $ · Last price: 15.50 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Adlai Nortye Ltd. ANL | 1.0 | – | 0.0 | 100.0 | -330.5 | – | 831.2 |
| Vertex Pharmaceuticals Inc VRTX | 133.1 | 31.9 | 24.4 | 55.0 | 38.1 | 9.6 | 37.8 |
| Regeneron Pharmaceuticals Inc REGN | 81.9 | 19.8 | 13.5 | 44.5 | 20.7 | 1.0 | 38.7 |
| Moderna Inc MRNA | 78.9 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| argenx NV ARGX | 59.7 | 36.7 | 31.5 | 59.1 | 32.0 | 89.6 | 31.9 |
| Revolution Medicines Inc RVMD | 42.6 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.0 |
| BeiGene, Ltd. ONC | 40.8 | 64.4 | 32.4 | 88.9 | 19.1 | 40.2 | 9.1 |
| Alnylam Pharmaceuticals Inc ALNY | 34.0 | 64.4 | 28.6 | 79.7 | 23.0 | 65.2 | -45.6 |
| Royalty Pharma Plc RPRX | 32.1 | 31.4 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 42.6 | 34.3 | 19.2 | 59.1 | 20.7 | 7.3 | 38.7 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | – | -19 | -18 | -2.10 | -15 | -69 | 11 |
| 2020 | – | -26 | -63 | -7.47 | -35 | -132 | 37 |
| 2021 | 46 | -9 | -57 | -4.61 | -3 | -185 | 132 |
| 2022 | 0 | -67 | -59 | -4.78 | -43 | -241 | 73 |
| 2023 | 5 | -73 | -109 | -16.05 | -57 | 75 | 130 |
| 2024 | 0 | -53 | -52 | -4.87 | -52 | 25 | 71 |
| 2025 | 5 | -36 | -36 | -3.33 | -34 | -8 | 34 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2023: Q1 | – | – | 0 | – | – | -10 | -10 |
| 2023: Q2 | -1.94 | – | 0 | – | – | -8 | -8 |
| 2023: Q3 | -0.24 | – | 3 | – | -529.10 | -19 | -19 |
| 2023: Q4 | -0.38 | – | 3 | – | -529.10 | -19 | -19 |
| 2024: Q1 | – | – | 1 | – | -1,853.20 | -14 | -14 |
| 2024: Q2 | -0.35 | 82.00 | 1 | – | -1,853.20 | -14 | -14 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.18 | -0.32 – -0.06 | 17 | 50.2% | 7 |
| 12/31/2027 | -0.29 | -0.70 – -0.08 | 8 | -59.7% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year -8.3%
- Share count grows by less than 3% a year -4.7%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion 100.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 55 m
- Return on capital at 15% or higher, or up versus two years ago no data
- Insiders hold at least 10% or are net buyers 0.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -42.5%
- Exp. sales growth 3Y > 5% 23.3%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 23.3%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% –
- Expected return > 10% 19.1%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | Ji Ping | Director | Sell | 5,000 | 16.63 | 83,150 |
| Aug 26, 2026 | Ye Xiaofeng | CFO | Sell | 5,667 | 14.25 | 80,755 |
| Aug 24, 2026 | Ye Xiaofeng | CFO | Sell | 6,000 | 13.98 | 83,880 |
The company
About the Company
Die Adlai Nortye Ltd., ein Unternehmen im klinischen Stadium, betreibt zusammen mit ihren Tochtergesellschaften Forschung und entwickelt Arzneimittel. Ihre Produktpipeline umfasst AN0025, einen niedermolekularen EP4-Antagonisten, der sich in Phase-Ib-Studien und in Kombination mit Strahlentherapie/Radiochemotherapie zur Behandlung von Rektum- und Speiseröhrenkrebs sowie in Phase-II-Studien für Patienten mit mittlerem bis hohem Risiko für Rektumkrebs befindet. Das Unternehmen entwickelt zudem AN9025, einen oralen niedermolekularen Pan-RAS(ON)-Inhibitor, der sich in Phase-1a-Studien zur Behandlung RAS-mutierter Krebserkrankungen befindet, einschließlich Bauchspeicheldrüsen-, Lungen- und kolorektaler Adenokarzinome; AN4035, ein firmeneigenes, auf CEACAM5 gerichtetes Antikörper-Wirkstoff-Konjugat, das eine starke Antitumoraktivität bei verbessertem therapeutischem Fenster liefern soll; sowie AN8025, ein trispezifisches Antikörper-Fusionsprotein, das sich in Phase-Ia-Studien zur Behandlung fortgeschrittener Tumoren befindet. Darüber hinaus entwickelt es AN4005, einen niedermolekularen PD-L1-Inhibitor, der durch die Blockade der PD-1/PD-L1-Interaktion Antitumoraktivität zeigt und sich in Phase-1b-Studien zur Aktivierung der Krebsimmunität befindet. Ferner ist das Unternehmen im Geschäft mit Technologietransfer und Beratungsdienstleistungen tätig. Die Adlai Nortye Ltd. wurde 2004 gegründet und hat ihren Hauptsitz in North Brunswick, New Jersey.
- Employees
- 109
- Headquarters
- Singapore, Singapore
- Address
- 77 Robinson Road, 068896 Singapore, Singapore
- Phone
- 848 230 7430
- Website
- adlainortye.com
- IPO Date
- 09/29/2023
- ISIN
- US00704R1095
Management
| Name | Title | Birth Year |
|---|---|---|
| Yang Lu EMBA | Co- Founder, CEO & Chairman | 1979 |
| Ngai Chiu Tse M.D., Ph.D. | President & Head of Research & Development | 1967 |
| Xiaofeng Ye Ph.D. | Chief Financial Officer | 1979 |
| Zhiyong Yu Ph.D. | Vice President of Operations | – |
| Chen Yang EMBA | Head of HR & Administration & Government Affairs | – |
| Donghui Yang | Chairman of the Greater China Region | – |
| Nanhai He Ph.D. | Head of Discovery | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.